The serotonergic system dysfunction in diabetes mellitus

Yan Cai†, Xiaolong Li†, Hongli Zhou and Jiyin Zhou*

National Drug Clinical Trial Institution, Second Affiliated Hospital, Army Medical University, Chongqing, China

Most peripheral serotonin (5-HT) is synthesized in enterochromaffin cells, and most circulating 5-HT is stored in platelets. As a monoamine, 5-HT has several functions in various non-neuronal and neuronal systems. In the central nervous system, it functions as a neurotransmitter to modulate feeding behavior and mood. Numerous clinical trials have focused on increasing 5-HT activation in the central nervous system, including those involving anti-obesity drugs currently in the market, although severe side effects on peripheral system can lead to the withdrawal of certain drugs. Recent studies have revealed that both the peripheral and central serotonergic systems play a vital role in diabetes and its complications. This review summarizes the roles of the serotonergic system in blood glucose regulation, diabetic macroangiopathy, diabetic peripheral neuropathy, and diabetic encephalopathy, indicating its potential clinical significance as a therapeutic target for the treatment of diabetes and its complications.

KEYWORDS
serotonin, 5-HT, diabetes, neuropathy, 5-HT receptor, hyperglycemia

Introduction

5-hydroxytryptamine (5-HT), also known as serotonin, has numerous functions in non-neuronal and neuronal systems. 5-HT was discovered in 1918 and was considered to be a vasoconstrictor stored in platelets. In 1937, 5-HT was discovered in enterochromaffin cells of the gastrointestinal tract and was called enteramine, since it was considered to induce smooth muscle contraction in the intestine (Erspamer and Asero, 1952). 5-HT was reported to be a neurotransmitter in 1952 (Brodie and Shore, 1957), and has been linked to appetite, behavior, mood, and sleep cycle regulation (Zucker, 1944). It is now known to function as a mitogen and hormone as well.

Most 5-HT in the periphery is synthesized by enterochromaffin cells (Sumara et al., 2012). As the rate-limiting enzyme for 5-HT production, tryptophan hydroxylase causes the hydroxylation of tryptophan to synthesize 5-HT. The synthesis of 5-HT occurs in two steps. In the first step, tryptophan hydroxylase (the rate-limiting enzyme for 5-HT production) metabolizes tryptophan to 5-hydroxytryptophan. In the second step, 5-hydroxytryptophan is decarboxylated to 5-HT by a nonspecific enzyme (aromatic L-amino acid decarboxylase). Thus, 5-HT synthesis is modulated...
by the availability of tryptophan and the activity of tryptophan hydroxylase. One of the two tryptophan hydroxylase isoforms, tryptophan hydroxylase 1, is mainly expressed in the peripheral tissues and also in the pineal gland, while the other, tryptophan hydroxylase 2, is chiefly expressed in a subset of neurons of the enteric and central nervous system, including those in the raphe nuclei of the brain stem (Malek et al., 2005; Li et al., 2011; Yabut et al., 2019). Although tryptophan hydroxylase 1 is extensively expressed in peripheral tissues, more than 90% of the total 5-HT in the body is synthesized in the intestine (Berger et al., 2009). Most peripheral 5-HT is stored in platelets and controls the hemodynamics upon platelet activation. Several recent studies have shown that 5-HT can be produced in other peripheral tissues, including in the pancreas, heart, and adipose tissue, and plays a role in the manner of cell-autonomous (Kim et al., 2010; Ponicke et al., 2012; Oh et al., 2015). 5-HT also acts autonomously on various cell types in the gastrointestinal, hematopoietic, cardiovascular, and immune systems, and in the liver, bone, and placenta (Amireault et al., 2013). Within the enteric and central nervous systems, 5-HT is produced and stored in presynaptic neurons. As 5-HT cannot physically cross the blood-brain barrier, the peripheral serotonergic system is functionally separate from the central serotonergic system.

5-HT modulates many physiological and pathological processes via several membrane-bound 5-HT receptors; moreover, the biological functions of 5-HT are restricted by its uptake into cells via 5-HT transporters (Wade et al., 1996). More than 14 5-HT receptors belonging to seven families mediate the different functions of 5-HT (Mohammad-Zadeh et al., 2008). The 5-HT3 receptor is a ligand-gated cation channel, while all other 5-HT receptors are G-protein-coupled receptors (Peroutka and Howell, 1994; Reeves and Lumnis, 2002). Recently, a novel detection technology was used in zebra fish model to show that 5-HT concentration significantly decreases in early diabetes, and that 5-HT can be used as an effective biomarker for the early diagnosis of diabetes (Khoshnevisan et al., 2021).

Several recent reviews have discussed the role of 5-HT and its receptors in neurological diseases and metabolism (Politis and Niccolini, 2015; Tu et al., 2015; Fakhoury, 2016; Oh et al., 2016; Lalut et al., 2017; Yohn et al., 2017; Yabut et al., 2019; Jones et al., 2020). Especially one review has summarized that 5-HT is produced in some peripheral tissues, including pancreas, adipose tissue, and liver; 5-HT and its receptors are involved in several metabolic pathways in peripheral tissues in the manner of cell-autonomous, such as insulin secretion and cell proliferation during development of β-cells, lipolysis in adipocytes, gluconeogenesis and glucose uptake in hepatocytes (Oh et al., 2016). So this review only summarizes the recent results regarding the roles of the peripheral and central serotonergic systems in diabetes and its complications, especially diabetic macroangiopathy, diabetic peripheral neuropathy, and diabetic encephalopathy.

Roles of the peripheral serotonergic system in blood glucose level regulation

Obese humans synthesize and release more 5-HT from the proximal small intestine, which is strongly associated with glycemic control and higher body mass. The 5-HT produced in the intestine is believed to be a vital driver of pathogenesis in human obesity and dysglycemia (Young et al., 2018). Pharmacological or genetic reductions in gut 5-HT protect against diet-induced obesity, hepatic steatosis and glucose intolerance (Sumara et al., 2012; Crane et al., 2015; Oh et al., 2015; Choi et al., 2018), illustrating a causative role of elevated gut-derived 5-HT in driving metabolic dysfunctions. Both the density of enterochromaffin cells and the expression of tryptophan hydroxylase 1 are increased in human obesity (Young et al., 2018); however, mechanisms driving such changes remain unknown. Interactions between intestine-produced 5-HT and gut microbiota have recently been hypothesized to regulate host glucose metabolism. Pharmacological suppression or knockout of tryptophan hydroxylase to abolish intestinal 5-HT synthesis in mice, with or without antibiotic-related microbiota elimination, shows remarkable amelioration of glucose clearance (Martin et al., 2019). The amelioration in host glucose clearance caused by antibiotic-induced alterations in microbiota composition are dependent on the production of intestine-derived 5-HT (Martin et al., 2019).

With regard to insulin resistance, inhibition of intestine-secreted 5-HT improves glucose tolerance in high-fat diet-induced mice (Sumara et al., 2012). In hepatocytes, intestine-secreted 5-HT signaling via the 5-HT2B receptor increases gluconeogenesis. Furthermore, intestine-derived 5-HT inhibits glucose uptake into hepatocytes through glucose transporter 2; hence, intestine-specific tryptophan hydroxylase 1 knockout mice and liver-specific 5-HT2B receptor knockout mice show improved glucose tolerance compared to wild-type mice (Sumara et al., 2012). Glycemic regulation is also ameliorated in tryptophan hydroxylase 1 knockout mice, although the glucose uptake rate is the same as in the liver, muscle, and heart, suggesting that brown adipose tissue makes a major contribution to the increased basal metabolic rate (Crane et al., 2015). The effects of the peripheral and central serotonergic
systems on blood glucose levels are shown in Table 1 and Figure 1.

5-HT receptor agonists induce hyperglycemia in rats

5-carboxamidotryptamine, a peripherally acting nonselective 5-HT receptor agonist, induces significant hyperglycemia in rats at doses higher than 0.05 mg/kg. The above mentioned dose of 5-carboxamidotryptamine causing hyperglycemia can induce other pharmacological effects (drinking or hypophagia) in rats (Yamada et al., 1998). 5-carboxamidotryptamine-induced hyperglycemia is mediated by the facilitation of adrenaline secretion. Moreover, 5-carboxamidotryptamine causes hyperglycemia via 5-HT7 receptors, but not 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2, 5-HT3, 5-HT4, and 5-HT5 receptors. This indicates that the 5-HT7

| Serotonergic system | Target | Effects | References |
|---------------------|--------|---------|------------|
| Intestine-secreted 5-HT | 5-HT2B receptor in hepatocytes | Increases gluconeogenesis, increases serum glucose level | Sumara et al., 2012 |
| 8-hydroxy-2-(di-n-propylamino)tetralin | Central nervous system | Increased corticosterone leads to increased plasma glucose levels | Gehlert and Shaw, 2014 |
| 5-carboxamidotryptamine | Peripherally acting nonselective 5-HT receptor agonist | Hyperglycemia in rats | Yamada et al., 1998 |
| Mirtazapine | 5-HT2 receptor antagonists | Worsens insulin sensitivity | Gilles et al., 2005 |
| Fluoxetine | 5-HT4 receptor agonist | Ameliorates insulin sensitivity | Breum et al., 1995 |
| Sertraline and paroxetine | Selective serotonin reuptake inhibitor | Improves glycemic control | Goodnick et al., 1997; Ueno et al., 2010 |
| Mosapride or prucalopride | Peripheral | Increases insulin release, elevates the serum insulin level accompanied by a decrease in blood glucose | Chen et al., 2016 |
| 5-HT3 receptor | Nucleus accumbens | Reduces the physiological drive to eat | Jean et al., 2007 |
| Lorcaserin | 5-HT1C receptor agonist | Loses weight and ameliorates glycemic parameters in prediabetes patients, and prevents progression to type 2 diabetes and accelerates reversion to normal blood glucose levels | Nesto et al., 2016 |
| Lorcaserin | Brainstem nucleus of solitary tract | Decreasing food intake when activated | D’Agostino et al., 2018 |
| Glucagon-like peptide 1 receptor | Dorsal raphe | Body weight reduction, anorexia, and fat mass loss; 5-HT turnover and expression of 5-HT2A and 5-HT1C receptors | Anderberg et al., 2017 |
| M-chlorophenylpiperazine | Peripherally acting 5-HT receptor agonist | Ameliorates insulin sensitivity and glucose homeostasis | Berglund et al., 2013 |
| Antagonists or genetic deletion of 5-HT2C receptors | Pro-opiomelanocortin neurons | Compromises glucose homeostasis | Berglund et al., 2013 |
| Transcutaneous auricular vagus nerve stimulation (2/15 Hz, 2 mA) | Systemic or intrathecal injection | Inhibits the progression of nociceptive hypersensitivity in Zucker diabetic fatty rats, this advantageous impact on nociceptive behavior is associated with an increase in 5-HT plasma levels and upregulated expression of the 5-HT1A receptor in the hypothalamus | Li et al., 2018 |
| Duloxetine | Inhibitor of serotonin and norepinephrine reuptake | Alleviates tactile allodynia in diabetic rats | Mixcoatl-Zecuatl and Jolivalt, 2011 |
FIGURE 1
Effects of peripheral and central serotonergic systems on blood glucose levels. 5-HT, 5-HT$_2$ receptor, 5-HT receptor agonists, 5-HT$_4$ receptor agonists, and 5-HT$_2C$ receptor agonists regulate blood glucose levels via the peripheral serotonergic system. 5-HT in the brain, pinealocytes, nucleus accumbens, and hypothalamus and 5-HT$_2C$ receptors in the hypothalamus and nucleus of the solitary tract are involved in modulating blood glucose levels via the central serotonergic system.

receptor may participate in adrenaline secretion like other 5-HT receptor subtypes (Yamada et al., 1998). 8-hydroxy-2-(di-n-propylamino)tetrinal, a 5-HT$_1A$ receptor agonist, causes hyperphagia and increases plasma glucose levels. It increases plasma corticosterone levels through a central nervous system mechanism, and increased corticosterone leads to higher plasma glucose levels (Gehlert and Shaw, 2014).

Role of the 5-HT$_2$ receptor in glucose metabolism

The 5-HT$_2$ receptor participates directly in glucose metabolism in humans (Gilles et al., 2005). This is closely related to the effects of pharmacological agents that function as 5-HT$_2$ receptor antagonists (such as mirtazapine), which can worsen insulin sensitivity and, in vulnerable patients or those with accompanying weight gain, may elevate the risk of impaired glucose tolerance and eventually diabetes. These observations confirm the hypothesis that serotonergic antidepressants directly deteriorate insulin sensitivity (Gilles et al., 2005). The 5-HT$_2A$ receptor is expressed on both human skeletal muscle cells (Hajduch et al., 1999b) and in adult rat skeletal muscle (Hajduch et al., 1999a). It can stimulate rapid glucose uptake in rat skeletal muscle in vitro, particularly in L6 myotubes (Hajduch et al., 1999b). Therefore, several drugs may damage insulin sensitivity at the level of 5-HT$_2$ receptor-mediated modulation of glucose transporters in muscle. To date, the antagonist property at 5-HT$_2A$ receptors of clozapine and olanzapine have been associated with antipsychotic-induced diabetes (Henderson, 2002). This may be due to the obvious drug-related weight gain (Nasrallah, 2003), highlighting another disadvantageous effect of impaired insulin sensitivity on metabolism. However, some data suggest that all 5-HT$_2$ receptor antagonists, including both these drugs, may pose a risk associated with insulin sensitivity (Gilles et al., 2005).

Fluoxetine, a selective serotonin reuptake inhibitor, induces the inhibition of 5-HT$_2C$ receptors, and its short-term treatment is linked to weight loss; however, it also appears to ameliorate insulin sensitivity beyond the efficacy produced via weight loss by a likely stimulating effect on glycogen synthase activity in skeletal muscle (Breum et al., 1995). Sertraline and paroxetine, selective serotonin reuptake inhibitors, though lacking direct 5-HT$_2C$ inhibiting properties, may also improve glycemic control (Goodnick et al., 1997; Païle-Hyvarinen et al., 2003).

5-HT$_2C$ receptor agonists prevent type 2 diabetes

Lorcaserin (Belviq, lorcaserin hydrochloride), a 5-HT$_2C$ receptor agonist, was the first drug approved by the U.S. Food and Drug Administration to treat obesity in 2010 (2012). Several studies have analyzed the impact of lorcaserin on the progression from prediabetes to type 2 diabetes and on the restoration of prediabetes blood glucose levels to normal levels (Higgins et al., 2020). It can result in weight loss and ameliorate glycemic parameters in prediabetes patients, and can prevent progression to type 2 diabetes and accelerate reversion to normal blood glucose levels (Nesto et al., 2016). It has also been shown to ameliorate glycemic control in relation to weight loss in obese patients with type 2 diabetes (Burke et al., 2017). Brain pro-opiomelanocortin peptides are essential and adequate neurochemical mediators of lorcaserin’s glucoregulatory influence. Lorcaserin dose-dependently ameliorates glycemic control in type 2 diabetes mice without decreasing food intake or body weight. It needs functional melanocortin-4 receptors on cholinergic preganglionic neurons to trigger its effects on glucose homeostasis (Burke et al., 2017). In contrast, melanocortin-4 receptors on cholinergic preganglionic neurons do not affect lorcaserin’s influence on feeding, suggesting a diversity in the neurocircuitry
underpinning lorcaserin’s curative glycemic and anorectic effects. A hyperinsulinemic-euglycemic clamp study revealed that lorcaserin decreases hepatic glucose synthesis, raises glucose disposal, and ameliorates insulin sensitivity (Burke et al., 2017). In its recently CAMELLIA-TIMI 61 trial (Scirica et al., 2019), there is a small raise in cancer in lorcaserin group, so the U.S. Food and Drug Administration asks the manufacturer to withdraw lorcaserin from the U.S. market in February 2021 (Mathai, 2021).

5-HT₄ receptor agonists reduce blood glucose level

Gastrointestinal diseases, including constipation and gastroparesis, are common in diabetic patients. As an agonist of the 5-HT₄ receptor, mosapride ameliorates these symptoms and controls the glycemic response (Ueno et al., 2010). The 5-HT₄ receptor is expressed in β-cells in mice, rats, pigs, and humans. Stimulation of the 5-HT₄ receptor with mosapride or prucalopride (a selective, high-affinity 5-HT₄ receptor agonist) induces insulin release in both pancreatic tissue and islet cells of rats in vitro. In rats, it also elevates the serum insulin level accompanied by a decrease in blood glucose (Chen et al., 2016).

Role of the central serotonergic system in eating and blood glucose regulation

Central serotonergic activity may modulate glucose metabolism via neuroendocrine effectors (Trento et al., 2010). There are obvious alterations in 5-HT levels in the prefrontal cortex, and in γ-aminobutyric acid and glutamate levels in the hippocampus in Spontaneously Diabetic Torii fatty rats compared with those in control rats (Sakimura et al., 2018). Hypothalamic 5-hydroxyindoleacetic acid concentrations in Goto-Kakizaki rats, a spontaneous diabetic model, were not different from those in control rats, whereas hypothalamic 5-HT concentrations in the streptozotocin-induced diabetic rats were significantly decreased (Gotoh et al., 2006). In addition, the expression of 5-HT₄ receptors in the hypothalamus can be modulated by serum glucose levels (Jhanwar-Uniyal et al., 1994).

5-HT in feeding and anorexigen action

Maintaining the energy balance requires modulation of the amount and timing of food intake, and eating disorders are emerging as a critical health issue in several developed countries. As confirmed in the central nervous system, 5-HT is a fundamental neurotransmitter regulating several physiological processes that affect food intake. The most important features of the serotonergic effects on energy balance pathways are linked to the regulation of the arcuate nucleus pro-opiomelanocortin and agouti-related peptide/neuropeptide Y neuronal populations. Previous studies have established that 5-HT hyperpolarizes and suppresses agouti-related peptide/neuropeptide Y neurons and decreases the suppressive drive onto pro-opiomelanocortin cells by stimulation of 5-HT₁B receptors. The 5-HT also activates pro-opiomelanocortin/cocaine- and amphetamine-regulated transcript neurons through activation of 5-HT₂C receptors (Heisler et al., 2006), which results in a reciprocal increase in α-melanocyte stimulating hormone secretion and decline in agouti-related peptide secretion at melanocortin 4 receptors in the target areas. Subsequent elevation of 5-HT neurotransmission also modulates the hypothalamic-pituitary-adrenal axis (HPA) upstream of the corticotropin-secreting hormone (Heisler et al., 2007). CP-809101 (a selective 5-HT₂C agonist) suppresses responding motivated by both food...
and nicotine in rats. CP-809101 inhibits the discriminative stimulus characteristics of nicotine with the same as Ro 60-0175 and lorcaserin (two structurally distinct 5-HT<sub>2C</sub> receptor agonists). Behaviors including hypolocomotion, ptosis, and chewing become evident after treated with both higher doses of lorcaserin and CP-809101. These results indicate that the use of 5-HT<sub>2C</sub> agonists as a therapeutic drug to treat nicotine dependence (Higgins et al., 2013).

The nucleus accumbens is a brain structure implicated in reward. Direct activation of 5-HT<sub>4</sub> receptors in the nucleus accumbens suppresses the physiological initiation to feed and upregulates mRNA expression of cocaine- and amphetamine-regulated transcript in food-deprived and fed mice (Jean et al., 2007). Knockdown of 5-HT<sub>4</sub> receptor with siRNA or injecting 5-HT<sub>4</sub> receptor antagonist into the nucleus accumbens causes hyperphagia uniquely in fed but not in food-deprived mice. In both food-deprived and fed mice, this hyperphagia is not linked to alteration in mRNA expression of cocaine- and amphetamine-regulated transcript in the nucleus accumbens. 5-HT<sub>4</sub> receptor regulates mRNA expression of cocaine- and amphetamine-regulated transcript into the nucleus accumbens through a cyclic adenosine monophosphate/protein kinase A signaling pathway (Jean et al., 2007). The nucleus accumbens 5-HT<sub>4</sub> receptor/cocaine- and amphetamine-regulated transcript pathway tightly connects between hyperactivity and anorexia, indicating the presence of a fundamental functional unit susceptible to inhibit overeating linked to resting abiding by the rules of homeostasis (Jean et al., 2012).

Decreased 5-HT levels in pinealocytes of diabetic pigs

Streptozotocin-induced diabetes significantly impacts sympathetic neurotransmission and the metabolism of melatonin synthesis-associated indoles in the pineal gland of pigs. The most prominent effect of diabetes on pig pinealocytes is the reduction in 5-HT levels. However, the synthesis of 5-HT is not influenced, since there is no change in 5-hydroxytryptophan content; therefore, two mechanisms that could result in the reduction in 5-HT content should be taken into account—increased utilization of 5-HT for N-acetylserotonin synthesis and insufficient storage of 5-HT (Lewczuk et al., 2018). The N-acetylserotonin level in the pineal gland of diabetic pigs is remarkably higher than that in control pigs; however, this is not reflected in an elevated melatonin content. Moreover, there were no discrepancies in the basal and adrenergic-induced secretion of melatonin and N-acetylserotonin between the pineal glands of control and diabetic pigs in vitro (Lewczuk et al., 2018).

Elevating brain 5-HT levels to treat diabetes

Intranasal 5-HT administration reduces the body weight of diabetic rats and improves glucose tolerance, insulin-induced glucose utilization, and lipid metabolism (Derkach et al., 2015). Moreover, it restores the hormonal modulation of adenyl cyclase activity in the hypothalamus and normalizes adenyl cyclase activation by β-adrenergic agonists in the myocardium. The same administration induces metabolic and hormonal changes in control rats, some of which resemble those in type 2 diabetes, but to a lesser degree. The elevation of brain 5-HT content may be considered an effective method to treat type 2 diabetes and its complications (Derkach et al., 2015). Several other studies show that the intranasal delivery of peptides or proteins is a potential method to overcome the obstacles of the blood–brain barrier (Lochhead and Thorne, 2012). But the pathways and mechanisms of molecules delivery to central nervous system from the nasal passages still need completely understood.

Role of hypothalamic 5-HT in hypoglycemic regulation

Insulin-induced hypoglycemia activates widespread 5-HT release in several forebrain areas, such as the ventromedial hypothalamus, perifornical hypothalamus, paraventricular hypothalamus, cerebral cortex, and paraventricular thalamic nucleus (Otlivanchik et al., 2015). In conscious rats, bilateral perifornical hypothalamic glucoprivation with 5-thioglucose significantly triggers adrenal medullary epinephrine secretion and feeding, while clamping perifornical hypothalamic glucose levels in the postprandial brain blunts the epinephrine response to hypoglycemia by 30%. The perifornical hypothalamus modulates adrenomedullary and feeding responses in the case of a metabolic emergency in freely behaving conscious rats. These responses are partly mediated by perifornical hypothalamic orexin neurons and 5-HT signaling (Otlivanchik et al., 2015). The perifornical hypothalamus has glucose-excited and glucose-inhibited neurons—glucose-excited neurons are principally excited, while glucose-inhibited neurons can be inhibited or excited by 5-HT at hypoglycemic glucose levels in vitro. 5-HT also stimulates lactate generation in hypothalamic astrocytes in vitro. Depleting perifornical hypothalamus 5-HT blunts the epinephrine (but not feeding) response to the focal perifornical hypothalamus and systemic glucoprivation, while raising the perifornical hypothalamus 5-HT level amplifies the epinephrine response to hypoglycemia by 32% (Otlivanchik et al., 2015). Perifornical hypothalamus 5-HT promotes the adrenomedullary response, and that perifornical hypothalamus orexin neurons change the electrophysiological properties of adrenal premotor neurons facilitating adrenaline release.
in response to glucopenia response to local and systemic glucose deficit (Korim et al., 2014). Selective serotonin reuptake inhibitors increase the counterregulatory response to acute hypoglycemia and avoid the blunting of the counterregulatory response after recurrent hypoglycemia in rats (Sanders et al., 2008) and humans (Briscoe et al., 2008a,b), indicating that 5-HT plays a vital role in mediating this response. These results suggest a critical role for 5-HT in strengthening the counterregulatory response to hypoglycemia. But it is still unknown how serotonergic system is activated in response to insulin-induced hypoglycemia. And whether serotonergic neurons are activated by either decreased glucose level or increased insulin level is still unknown.

**Role of nucleus accumbens 5-HT in blood glucose homeostasis**

The nucleus accumbens is part of the reward circuitry that regulates feeding behavior. It contains glucose-sensing neurons (Papp et al., 2007) and provides input to the lateral hypothalamus (Groenewegen and Russchen, 1984), another region involved in glucose control (Yi et al., 2009; Morgan et al., 2015). Electrical stimulation of the shell nucleus accumbens using deep brain stimulation raises plasma levels of glucagon and glucose and stimulates neurons in the lateral hypothalamus (Diepenbroek et al., 2013), indicating a role for the shell nucleus accumbens in the modulation of glucose homeostasis. Locally infusing fluoxetine, a 5-HT reuptake inhibitor, in the shell nucleus accumbens of rats elevates blood glucose levels without overall altering glucoregulatory hormones, such as glucagon, insulin, and corticosterone. Its mechanism is not via the activity of the autonomic nervous system, since the glucagon level is not impacted. The effect on glucose levels might be due to the combined effects of higher endogenous glucose production and direct effect of 5-HT availability in the shell area of the nucleus accumbens on peripheral glucose uptake. Since peripheral glucose uptake is regulated by hypothalamus (Sudo et al., 1991) and the hypothalamus receives dense projections from the shell area of the nucleus accumbens (Sano and Yokoi, 2007). These results establish a role for the shell nucleus accumbens in systemic glucose metabolism and indicate that 5-HT may play a vital role in mediating these effects (Diepenbroek et al., 2017).

**5-HT_{2C} receptors in the nucleus of the solitary tract and hypothalamus modulate food intake and glucose homeostasis**

Selective stimulation of 5-HT_{2C} receptors in the nucleus of the solitary tract in the brainstem reduces feeding and is adequate to mediate acute food intake decrease induced by the use of lorcaserin, a 5-HT_{2C} receptor agonist, as an obesity medication (D’Agostino et al., 2018). A subpopulation of hypothalamic neurons in the brainstem nucleus of solitary tract resemble pro-opiomelanocortin neurons in the hypothalamic arcuate nucleus and co-express 5-HT_{2C} receptors and are stimulated by 5-HT_{2C} receptor agonists. Deletion of 5-HT_{2C} receptors in the hypothalamic arcuate nucleus inhibits the acute appetite-inhibitive function of lorcaserin; conversely, deletion in the hypothalamic arcuate nucleus prevents the total anorectic effect. These results indicate that 5-HT_{2C} receptors in the brainstem nucleus of the solitary tract represent a subpopulation of 5-HT_{2C} receptors that are capable of decreasing food intake when activated, and reveal that 5-HT_{2C} receptor agonists as obesity medications need pro-opiomelanocortin in the nucleus of the solitary tract and the arcuate nucleus to reduce food intake (D’Agostino et al., 2018).

Mice lacking 5-HT_{2C} receptors, especially in pro-opiomelanocortin neurons, show normal body weight but exhibit glucoregulatory defects, such as hyperglycemia, hyperglucagonemia, hyperinsulinemia, and insulin resistance (Berglund et al., 2013). In addition, these mice have no anorectic responses to serotonergic agents that inhibit appetite and gradually become hyperphagic and obese after being fed a high-fat/high-sugar diet. The demand for 5-HT_{2C} receptors in pro-opiomelanocortin neurons to maintain normal energy and glucose homeostasis is further indicated by the effects of 5-HT_{2C} knockout in pro-opiomelanocortin neurons in adult mice using a tamoxifen-inducible pro-opiomelanocortin-Cre system (Berglund et al., 2013). Treatment with m-chlorophenylpiperazine, a non-selective 5-HT_{2C} receptor agonist, ameliorates insulin sensitivity and glucose homeostasis, and antagonists [ritanserin (a 5-HT_{2} and 5-HT_{1A} antagonist) and MDL 72222 (a 5-HT receptor antagonist)] or genetic deletion of 5-HT_{2C} receptors compromises glucose homeostasis (Berglund et al., 2013). These results show that 5-HT_{2C} receptor-expressing pro-opiomelanocortin neurons are required to regulate energy and glucose homeostasis and imply that pro-opiomelanocortin neurons are the target for the effect of 5-HT_{2C} receptor agonists on weight reduction and glycaemia regulation (Berglund et al., 2013). Postsynaptic receptors, such as 5-HT_{1B}, 5-HT_{2C}, and possibly 5-HT_{2B}, receptors, are assumed to be directly stimulated by dexfenfluramine-induced 5-HT transporter-dependent and 5-HT_{2B} receptor-dependent 5-HT secretion (Banas et al., 2011).

5-HT_{2C} receptors expressed by pro-opiomelanocortin neurons of hypothalamic arcuate nucleus modulate food intake, energy homeostasis, and glucose metabolism. A subpopulation (about 25%) of the hypothalamic arcuate nucleus neurons, which areas are differ from leptin-activated, are depolarized by the 5-HT_{2C} receptors agonist (m-chlorophenylpiperazine) through activation of the putative transient receptor potential C channels (Sohn et al., 2011). With this consistent mechanism, to record the brainstem nucleus of the solitary tract neurons
in a voltage clamp and treated with tetrodotoxin to antagonize the inhibitory effect of 5-HT, 5-HT, and lorcaserin excite the brainstem nucleus of the solitary tract neurons through the activation of a post-synaptic, mixed cationic current (D’Agostino et al., 2018).

5-HT as a substrate of glucagon-like peptide 1 to impact energy homeostasis

5-HT depletion impairs the effect of exendin-4, a glucagon-like peptide 1 analog, to reduce body weight in rats, indicating that 5-HT is a vital mediator of the energy balance-related effect of glucagon-like peptide 1 receptor stimulation. 5-HT turnover and expression of 5-HT$_{2A}$ and 5-HT$_{2C}$ receptors in the hypothalamus are also altered by glucagon-like peptide 1 receptor activation (Anderberg et al., 2017). The 5-HT$_{2A}$ receptor is significantly associated with body weight reduction, anorexia, and fat mass loss caused by central glucagon-like peptide 1 receptor activation. Importantly, 5-HT$_{2A}$ receptors in the brain are also needed for peripherally administered liraglutide, a glucagon-like peptide-1 receptor agonist, to decrease feeding and body weight (Anderberg et al., 2017). The dorsal raphe harbors the cell bodies of 5-HT-synthesizing neurons that provide 5-HT to the hypothalamic nuclei. Glucagon-like peptide 1 receptor activation in the dorsal raphe is sufficient to lower hypoglycemia and elevate the electrical activity of serotonergic neurons in the dorsal raphe. This identifies 5-HT as a novel pivotal region affected by glucagon-like peptide 1 receptor activation (Anderberg et al., 2017).

Role of the serotonergic system in diabetic macroangiopathy

5-HT is a significant vasoactive monoamine in the cardiovascular system. Reduction of 5-HT levels in platelets and elevation in plasma concentration may reflect increased secretion of 5-HT by hyperactive platelets. This elevation in plasma 5-HT levels may lead to the pathogenesis of vasospasm and atherosclerosis (Barradas et al., 1988), an important feature of cardiovascular diseases in diabetes (Forbes and Cooper, 2013).

Plasma 5-HT levels are elevated in diabetic patients, and this elevation is associated, at least in part, with platelet hyperfunction (Hasegawa et al., 2002). Although 5-HT-induced platelet aggregation is enhanced in diabetic patients, with an increase in serum advanced glycation end-product levels, there is no association between platelet aggregation and either fasting blood glucose or hemoglobin A1C levels. 5-HT-stimulated platelet aggregation is dose-dependently increased by advanced glycation end-products. Adenosine diphosphate-activated platelet aggregation is also enhanced by advanced glycation end-products; moreover this increase is abolished by the action of sarpogrelate, a selective 5-HT$_{2A}$ receptor antagonist (Hasegawa et al., 2002). These results suggest that advanced glycation end-products enhance platelet aggregation via the 5-HT receptor and may influence the development of thrombotic complications in diabetic patients (Hasegawa et al., 2002).

5-HT$_{2A}$ receptors in diabetes-related vascular complications

5-HT, stimulated by damaged vascular endothelial cells, participates in the pathological process of vascular complications such as carotid artery contraction (Matsumoto et al., 2014) and arteriogenesis (Bir et al., 2008) in diabetes via the 5-HT$_{2A}$ receptor. Sarpogrelate, a 5-HT$_{2A}$ receptor antagonist, attenuates diabetic cardiovascular complications; it decreases the blood glucose concentration (Matsumoto et al., 2014), inhibits the production of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 (Su et al., 2013), and reduces 5-HT-triggered contraction in aortas via PI3K pathways (Matsumoto et al., 2014). Combined sarpogrelate and sustained-release basic fibroblast growth factor therapy is effective in inducing neovascularization to restore arteriogenesis and tissue blood perfusion in diabetic mice (Bir et al., 2008). High glucose levels increase intercellular adhesion molecule-1 expression and decrease superoxide dismutase activity; these effects are partially abolished by sarpogrelate hydrochloride administration (Lin et al., 2007).

Enhanced contraction of arteries in type 2 diabetic mice is chiefly mediated by smooth muscle signaling pathway alterations that modulate calcium sensitivity of contractile proteins, rather than an alteration in endothelial-derived vasoactive factors or special 5-HT receptor subtypes (Nelson et al., 2012). 5-HT causes contraction via the activation of both 5-HT$_{2A}$ and 5-HT$_{2B}$ receptors in both diabetic and control mice. 5-HT$_{1B}$ receptor expression is detectable, but does not participate in the contraction in response to 5-HT in either diabetic or control mice, because there is no response to the 5-HT$_{1B}$ receptor agonist CP93129 (Nelson et al., 2012). Aberrant endothelial factors modulated by nitric oxide synthase and cyclooxygenase are also not involved in the increased contractions in response to 5-HT since endothelium removal; similarly, nitro-L-arginine and indomethacin do not have any obvious impact on contractions in response to 5-HT in the aorta in either diabetic or control mice. Contractions increase in response to all 5-HT$_{2A}$ and 5-HT$_{2B}$
receptor agonists, and suppression of both 5-HT_{2A} and 5-HT_{2B} receptors inhibits contraction response to 5-HT in arteries from diabetic mice. This occurs due to altered expression of either receptor subtype in diabetic arteries (Nelson et al., 2012). Contractions in response to 5-HT and both 5-HT_{2A} and 5-HT_{2B} receptor agonists are diminished by inhibiting Rho kinase. Receptor-independent contractions of diabetic arteries to KCl are also enhanced and partly mediated by Rho kinase (Nelson et al., 2012). In most arteries, serotonin-induced contractions are mediated by 5HT_{2A} receptors on vascular smooth muscle, which activates the Rho/Rho kinase pathway to regulate phosphorylation of myosin light chain phosphatase and myosin light chain (Dreja et al., 2002; Nuno et al., 2007). These results suggest that an alteration in rho kinase modulation of calcium sensitivity, but not 5-HT receptor expression, may mediate the hypercontractility of arteries from diabetics.

5-HT_{1B} receptors in peripheral arterioles

Cardiopulmonary bypass is linked to a decline in the contractile response of peripheral arterioles to 5-HT, which is exacerbated in diabetes. This 5-HT-stimulated contractile response of peripheral arterioles is mediated by the 5-HT_{1B} receptor in both non-diabetic and diabetic patients (Sabe et al., 2018).

5-HT_{2A} receptor antagonists in thrombosis

Polyethylene tube-induced thrombus formation was significantly elevated in streptozotocin-induced diabetic rats compared to that in normal rats (Yamada et al., 2012). Both 5-HT and high glucose upregulate the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells, and this upregulation is further enhanced by the combination of 5-HT and high glucose. Sarpogrelate, a 5-HT_{2A} receptor antagonist, but not aspirin, inhibits the increased expression of vascular cell adhesion molecule-1 triggered by 5-HT and high glucose (Yamada et al., 2012). These results imply that 5-HT drives the increased thrombogenesis in diabetes and that 5-HT_{2A} receptor antagonists may be potential novel candidates to treat diabetic complications.

5-HT receptors in retinal superoxide generation

Reactive oxygen species play a crucial role in the pathogenesis of diabetic retinopathy. Incubating cells or retinal explants in 30 mmol/L glucose significantly activated superoxide generation compared to incubation in 5 mmol/L glucose (Du et al., 2015). This response is diminished or blocked by pharmacological inhibition of the α1-adrenergic receptor (a G_{q}-coupled receptor) or G_{i}-coupled 5-HT receptors (5-HT_{4}, 5-HT_{6}, and 5-HT_{7}) or by activation of the G_{q}-coupled α2-adrenergic receptor. Links between different G protein-coupled receptor pathways regarding superoxide generation may originate from hyperglycemia-induced elevations in cytosolic Ca^{2+} levels (Du et al., 2015).

5-HT in diabetic vasculopathy

Levels of blood 5-HT in diabetic retinopathy patients are significantly lower than those in non-diabetic retinopathy patients (Pietraszek et al., 1992), while plasma 5-HT concentration is significantly elevated in diabetes. This is linked to vascular alterations in the retina. Platelets in diabetic patients take up less 5-HT than those in non-diabetic patients, spontaneous secretion of 5-HT from platelets is concomitantly enhanced, and platelets show an increased response to 5-HT. However, 5-HT-stimulated aggregation is not related to the presence of retinopathy (Pietraszek et al., 1992). These data indicate that 5-HT may be involved in the pathogenesis of diabetic vasculopathy.

Role of selective serotonin reuptake inhibitors in diabetes-related cardiovascular complications

Escitalopram, a selective serotonin reuptake inhibitor, improves high-fat/high-fructose diet- and streptozotocin-induced metabolic and cardiac impairment characteristics, such as inflammation, oxidative stress, apoptosis, fibrosis, hypertrophy, and impaired conduction (Ahmed et al., 2020). These benefits may be secondary to its primary beneficial effects on blood glucose control and, consequently, the downregulated expression of receptor for advanced glycation end-product. Escitalopram can be deemed a profitable antidepressant drug in diabetic patients because it ameliorates blood glucose control in diabetes and can also prevent diabetes-related cardiovascular complications (Ahmed et al., 2020).

Roles of the serotonergic syste in diabetic peripheral neuropathy

Hyperglycemia is no longer regarded as a unique etiological factor for diabetic peripheral neuropathy (Nelson et al., 2012; Sabe et al., 2018), as painful neuropathy is also a common comorbidity in patients with diabetes. The roles of the
serotonergic system in diabetic peripheral neuropathy and diabetic encephalopathy are described in Figure 2.

Spinal 5-HT

Painful diabetic neuropathy activates neuronal hyperactivity in the periaqueductal gray and spinal cord. As a critical region in descending nociceptive regulation, the periaqueductal gray makes use of relay stations in the noradrenergic and serotonergic brainstem regions. Streptozotocin-induced diabetic rats present with chemical allostodynia and mechanical hyperalgesia, coupled with higher spinal levels of noradrenaline and 5-HT and more neurons expressing tryptophan hydroxylase in the rostral ventrolateral medulla and tyrosine hydroxylase in the A5 noradrenergic cell group (Morgado et al., 2011). Administration of insulin growth factor 1 prevents the behavioral signs of painful diabetic neuropathy and restores the neuronal hyperactivity in the spinal cord and ventrolateral periaqueductal gray and the neurochemical alterations in the brainstem and spinal cord. Based on the facilitatory role of noradrenergic and serotonergic descending regulation during chronic pain, the elevated 5-HT and noradrenaline innervation of the dorsal horn in streptozotocin-induced diabetic rats may explain the pain reinforcement during painful diabetic neuropathy. The protective effects of insulin growth factor 1 in painful diabetic neuropathy are likely due to the inhibition of increased peripheral input to the somatosensory system, but direct central effects cannot be excluded (Morgado et al., 2011).

Serum 5-HT and 5-HT1A receptors in the hypothalamus

Zucker diabetic fatty (fa/fa) rats progress to type 2 diabetes spontaneously with aging and exhibit nociceptive hypersensitivity at 13-week of age. Daily 30-min transcutaneous auricular vagus nerve stimulation (2/15 Hz, 2 mA) for 27 consecutive days significantly inhibited the progression of nociceptive hypersensitivity in Zucker diabetic fatty rats, as measured based on mechanical allodynia and thermal hyperalgesia in the hindpaw. This advantageous impact on nociceptive behavior is associated with an increase in 5-HT plasma levels and upregulated expression of the 5-HT1A receptor in the hypothalamus (Li et al., 2018).

5-HT2A receptors in the spine

Systemic or intrathecal injection of duloxetine, a dual inhibitor of serotonin and norepinephrine reuptake, alleviates tactile allodynia in diabetic rats (Mixcoatl-Zecuatl and Jolivalt, 2011). The effect of systemic duloxetine administration is inhibited by intrathecal injection of ketanserin (a non-selective 5-HT2A receptor antagonist) or pruvanserin (a selective 5-HT2A receptor antagonist), suggesting the involvement of spinal 5-HT2A receptors in the mechanism of action of duloxetine. Compared with spinal injection, local peripheral and systemic administration of ketanserin or pruvanserin relieve tactile allodynia in diabetic rats. This effect is restored immediately after local or systemic administration of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride, a 5-HT receptor agonist (Mixcoatl-Zecuatl and Jolivalt, 2011). These data suggest a role of spinal 5-HT2A receptors in the effect of duloxetine in improving painful diabetic neuropathy. These results also show that the role of 5-HT2A receptors relies on the neuraxis level where activation occurs, with peripheral activation resulting in tactile allodynia in diabetic rats; conversely, spinal activation of this receptor relieves tactile allodynia.

Lower urinary tract impairment is one of the most common diabetic complications. The 5-HT2A receptor in spinal micturition control is involved in urethane anesthetized diabetes rats. Intravenous injection of the 5-HT2A/C receptor agonist (2,5-methoxy-4-iodoamphetamine) triggers high frequency oscillations and ameliorates micturition (Tu et al., 2015). Expressions of 5-HT2A receptor and 5-HT2C receptor are raised in lumbosacral cord motoneurons, and the number of serotonergic paraneurons are declined in the urethra in diabetes rats (Cao et al., 2019). The function of lower number of urethral paraneurons in diabetes still needs to be clarified but may be associated with the decreased urethral sensation induced by diabetes.

5-HT6 receptors in the spine

The 5-HT6 receptor accurately regulates critical neurodevelopmental processes, such as migration and differentiation of neuron (Chaumont-Dubel et al., 2020). The activation of 5-HT6 receptors leads to the activation of adenyly cyclase and may have an excitatory efficiency on neuronal activity (Ruat et al., 1993). Although there are very few studies on the role of 5-HT6 receptors in nociception, these receptors seem to mediate pronociceptive efficacies in the spinal cord and the periphery. Pharmacological suppression of 5-HT6 receptors diminishes formalin-stimulated nociceptive behavior (Finn et al., 2007), and spinal and local peripheral 5-HT6 receptors have a pronociceptive role in formalin-triggered pain (Castaneda-Corral et al., 2009).

Spinal nerve damage results in a loss of descending serotonergic neurons (Leong et al., 2011); in contrast, it does not alter spinal 5-HT6 receptor expression (Morgado et al., 2011). Differentiation from nerve injury-caused neuropathy,
Moreover, higher plasma levels of 3-indolepropionic acid are associated with a lower risk of type 2 diabetes (Tuomainen et al., 2018).

**Antidepressant-like action of brain 5-HT**

Neuropathological depletion of brain monoaminergic activity, due to chronic diabetes, specifically with regard to the 5-HT system, may result in mood- and behavior-related complications that further reduce the quality of life. Hypothalamic-pituitary-adrenal activity, insulin signaling, and glycogen synthase kinase 3 modulations are hampered and interlinked to the serotonergic system following diabetic progression (Prabhakar et al., 2015).

Disorder of the serotonergic system is a sign of diabetes-related depression. Reduced central 5-HT levels can be mediated by diabetes-induced inflammation and oxidative stress in the central nervous system. Oxidative stress results in dysfunction of the glucocorticoid receptor, negative feedback impairment, and altered functioning of the HPA axis. Hyperactivity of the HPA axis increases glucocorticoid secretion, which in turn inhibits 5-HT synthesis (Prabhakar et al., 2015). On the contrary, neuroinflammation in diabetes modulates the secretion of cytokines, which decreases 5-HT synthesis, increases 5-HT reuptake, and finally reduces its availability (Felger and Lotrich, 2013). In diabetic rats, the levels of 5-HT and brain-derived neurotrophic factor in the cortex and hippocampus are reduced, and serum corticosterone levels are elevated, which suggests hyperactivity of the HPA axis.

A single facial injection of botulinum neurotoxin A induces a quick and extended amelioration of depression-like behaviors in naive and space-restriction-stressed mice, with reduced duration of immobility in behavioral despair tests. Botulinum neurotoxin A significantly increases the 5-HT levels in numerous brain areas, such as the hippocampus and hypothalamus, in space-restriction-stressed mice (Li et al., 2019). It was also shown to increase the expression of N-methyl-D-aspartate receptor subunits NR1 and NR2B in the hippocampus, which are significantly downregulated in space-restriction-stressed mice. Furthermore, botulinum neurotoxin A significantly increases the expression of brain-derived neurotrophic factor in the hypothalamus, hippocampus, amygdala, and prefrontal cortex, which are downregulated in space-restriction-stressed mice. Botulinum neurotoxin A also momentarily upregulates the expression of phosphorylated extracellular signal-regulated kinase and phosphorylated cAMP-response element binding protein, which are downregulated in the hippocampus of space-restriction-stressed mice (Li et al., 2019). These data demonstrate that botulinum neurotoxin A administration has an antidepressant-like effect on mice, which is linked to elevated 5-HT levels and the activation of brain-derived neurotrophic factor/extracellular signal-regulated
kinase/cAMP-response element binding protein pathways in the hippocampus, backing further research on botulinum neurotoxin A treatment in depression.

5-HT$_3$ receptor antagonists in diabetes-induced depression

5-HT is one of the most frequently imbalanced neurotransmitters in the etiology of major depressive disorder, and this system is the chief target of most medications for the treatment of depression (Yohn et al., 2017). Antidepressants treatment in adults increases the risk of developing new-onset type 2 diabetes. Proof from human and animal studies indicates a relationship between increased risk of diabetes and the use of antidepressants that act on 5-HT signaling, such as 5-HT-norepinephrine reuptake inhibitors, 5-HT antagonist and reuptake inhibitors, and noradrenergic and specific serotonergic antidepressants (De Long et al., 2015). Spontaneously Diabetic Torii fatty rats exhibit depression-like behaviors and altered baseline HPA activity. In addition, neurotransmitter levels are dysregulated in the brain areas involved in the pathophysiology of depression (Sakimura et al., 2018).

Diabetic mice also show remarkable behavioral deficiencies, such as anxiety-like behavior in the open field test, depression-like behavior in the forced swim test, and sociability deficits in the social interaction test, accompanied by an obvious decline in 5-HT content in the associated brain areas (Gupta et al., 2016). Similar to fluoxetine, a selective serotonin reuptake inhibitor, N-(3-chloro-2-methylphenyl)quinazoline-2-carboxamide (1 mg/kg), prevents these behavioral deficits and normalizes brain 5-HT levels. N-(3-chloro-2-methylphenyl)quinazoline-2-carboxamide (0.5 mg/kg) ameliorated only diabetes-induced depressive-like behavior and 5-HT decrease, but not anxiety-like effects. 1-(m-chlorophenyl)-biguanide, a 5-HT$_3$ receptor agonist, blunted the N-(3-chloro-2-methylphenyl)quinazoline-2-carboxamide-activated behavioral response and elevated brain 5-HT levels (Gupta et al., 2016). These results suggest that N-(3-chloro-2-methylphenyl)quinazoline-2-carboxamide prevents diabetes-induced depressive phenotypes in mice, which may be attributed to the antagonism of 5-HT$_3$ receptors and elevation in 5-HT levels in different brain areas.

5-HT$_{1A}$ receptors in panic disorder in type 1 diabetes

Diabetic animals exhibit dysregulation of the serotonergic system in some brain regions linked to anxiety-like responses. In one study, 4 weeks after diabetic identification, the threshold of electric stimulation of the dorsal periaqueductal gray to reduce escape behavior in diabetic rats was found to be lower than that in normoglycemic rats (Gambeta et al., 2017); open-field test results indicated that there were no negative effects on locomotor activity in diabetic rats compared with normoglycemic rats. Intra-dorsal administration of the 5-HT$_{1A}$ receptor agonist (±)-8-hydroxy-2-(di-n-propylamino)tetralin in the periaqueductal gray increases the increment threshold in both diabetic and normoglycemic rats, indicating a panicolytic-like effect. Diabetic rats present with a more significant panicolytic-like response than normoglycemic rats, since a higher increment threshold was measured after 8-hydroxy-2-(di-n-propylamino)tetralin treatment, which could be a result of the upregulated expression of 5-HT$_{1A}$ receptors in the dorsal periaqueductal gray in diabetic rats (Gambeta et al., 2017). These data suggest that a lack of serotonergic regulation of the dorsal periaqueductal gray is involved in initiating the panic attacks and that 5-HT$_{1A}$ receptors might be critical for the panicolytic-like response.

Conclusion

There are two serotonergic systems in the human body—the central system and the peripheral system. With regard to the central serotonergic system, elevating 5-HT signaling has been used to therapeutically reduce body weight by inhibiting appetite. 5-HT is also thought to function in vasospasm and increase platelet aggregability, which can cause atherosclerosis. In peripheral tissues, inhibiting 5-HT signaling may represent a novel anti-obesity treatment by reducing energy expenditure and ameliorating insulin resistance (Crane et al., 2015; Oh et al., 2015). Systemic tryptophan hydroxylase 1 inhibitors and a peripheral tryptophan hydroxylase 1 inhibitor (LP-533401) have been patented for use in treating diabetes and obesity (Kolodziejczak et al., 2015; Abg Abd Wahab et al., 2019). However, there are still no clinical trials on the use of these drugs for the treatment of diabetes.

Upregulated expression of 5-HT$_{2C}$ receptors in both β-cells and the hypothalamus can be a protective strategy to avoid redundant energy intake. 5-HT$_{2C}$ receptor-expressing pro-opiomelanocortin neurons are required to regulate energy and glucose homeostasis (Berglund et al., 2013). Central 5-HT$_{2C}$ receptors control glucose homeostasis and could be a rational target for the treatment of type 2 diabetes. 5-HT$_{1A}$ receptors are broadly expressed in the central nervous system (Zhang and Stackman Jr., 2015) and are needed for peripherally administered liraglutide to decrease feeding and body weight (Anderberg et al., 2017). Brain serotonergic deficiencies are linked to depressive-like behavior in diabetes and selective serotonin reuptake inhibitors prevent these behavioral deficits and normalizes brain 5-HT levels (Gupta et al., 2016).

There is limited options for the investigation of the role of central serotonergic system in diabetes in humans in vivo. The
data in the present review are focused mostly on the results obtained from different animal models of diabetes. Additional experimental data on humans are expected to support this view in the future.

Author contributions

JZ, YC, and XL conceptualized the topics. JZ, YC, XL, and HZ wrote and revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of Chongqing (No. 81770806), the Natural Science Foundation of China (No. 81770806), and Special Project for Enhancing Science and Technology Innovation Ability of Army Medical University (No. 2019XYY16).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of the affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Abg Abd Wahab, D. Y., Gau, C. H., Zakaria, R., Muthu Karuppan, M. K., Bhat, A. R., et al. (2019). Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour. Biomed. Res. Int. 2019:176203. doi: 10.1155/2019/176203

Ahmed, L. A., Shiha, N. A., and Attia, A. S. (2020). Escitalopram ameliorates cardiomyopathy in type 2 diabetic rats via modulation of receptor for advanced glycation end products and its downstream signaling cascades. Front. Pharmacol. 11:579206. doi: 10.3389/fphar.2020.579206

Amireault, P., Sibon, D., and Cote, F. (2013). Life without peripheral serotonin: insights from tryptophan hydroxylase 1 knockout mice reveal the existence of paracrine/autocrine serotoninergic networks. ACS Chem. Neurosci. 4, 64–71. doi: 10.1021/cn3003154

Anderberg, R. H., Richard, J. E., Ererola, K., Lopez-Ferreras, L., Banke, E., Hansson, C., et al. (2017). Glucagon-Like peptide 1 and its analog act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight. Diabetes Metab. Res. Rev. 66, 1062–1073. doi: 10.2337/db16-0755

Banasz, S. M., Doly, S., Bournouriinsky, K., Diaz, S. L., Belmer, A., Callebert, J., et al. (2011). Deconstructing obesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology 36, 423–433. doi: 10.1038/npp.2010.173

Barradas, M. A., Gill, D. S., Fonseca, V. A., Mubahid, D. P., and Dandona, P. (1988). Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur. J. Clin. Invest. 18, 399–404. doi: 10.1111/j.1365-2362.1988.tb01030.x

Berger, M., Gray, J. A., and Roth, B. L. (2009). The expanded biology of serotonin. Annu. Rev. Med. 60, 355–366. doi: 10.1146/annurev.med.60.040207.110802

Berglund, E. D., Liu, C., Sohn, J. W., Liu, T., Kim, M. H., Lee, C. E., et al. (2013). Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. J. Clin. Invest. 123, 5061–5070. doi: 10.1172/JCI70338

Bir, S. C., Fujita, M., Marui, A., Arai, Y., Sakaguchi, H., et al. (2008). New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. Circ. J. 72, 633–640. doi: 10.1253/circj.72.633

Breum, L., Bjerre, U., Bak, J. F., Jacobsen, S., and Astrup, A. (1995). Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 44, 1570–1576. doi: 10.1016/0026-0495(95)90077-2

Briscoe, V. J., Ertl, A. C., Tate, D. B., and Davis, S. N. (2008a). Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes Metab. Res. Rev. 57, 3315–3322. doi: 10.2337/db10-1000

Briscoe, V. J., Ertl, A. C., Tate, D. B., Dawling, S., and Davis, S. N. (2008b). Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes Metab. Rev. 57, 2453–2460. doi: 10.2337/db08-0236

Brodie, B. B., and Shore, P. A. (1957). A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann. N. Y. Acad. Sci. 66, 631–642. doi: 10.1111/j.1749-6632.1957.tb08753.x

Buzko, L. K., Ogugnoowo-Bada, E., Georgescu, T., Cristiano, C., De Morentin, P. B. M., Valencia Torres, L., et al. (2017). Lorcaserin improves glycemic control via a melanocortin neurocircuit. Mol. Med. 6, 1092–1102. doi: 10.1016/j.molmed.2017.07.004

Cao, N., Huang, J., Ni, J., Si, J., Gu, B., Wang, Z., et al. (2019). Streptozotocin-induced diabetes causes upregulation of serotonin (5-HT)(2A/C) receptors in lumbosacral cord motoneurons and down regulation of serotoninergic paraneurons in the urethra. Brain Res. 1715, 21–26. doi: 10.1016/j.brainres.2019.03.009

Castaneda-Corral, G., Rocha-Gonzalez, H. I., Arauza-Saldana, C. I., Ambroz-Tuttati, M., Vidal-Cantu, G. C., and Granados-Soto, V. (2009). Role of peripheral and spinal 5-HT6 receptors according to the rat formalin test. Neuroscience 162, 444–452. doi: 10.1016/j.neuroscience.2009.04.072

Chaumont-Dubel, S., Dupoy, V., Bockaert, J., Becamel, C., and Martin, P. (2020). The 5-HT6 receptor interactome: new insight in receptor signaling and its impact on brain physiology and pathologies. Neuropharmacology 172:107839. doi: 10.1016/j.neuropharm.2019.107839

Chen, H., Hong, F., Chen, Y., Li, J., Yao, Y. S., Zhang, Y., et al. (2016). Activation of uter 5-HT4 receptor regulates glycemic control through promoting insulin secretion. Eur. J. Pharmacol. 789, 354–361. doi: 10.1016/j.ejphar.2016.07.024

Choi, W., Namkung, J., Hwang, I., Kim, H., Lim, A., Park, H. J., et al. (2018). Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat. Commun. 9:4824. doi: 10.1038/s41467-018-07287-7

Cramer, J. D., Paliavel, R., Mottillo, E. P., Bojak, A. L., Wang, H., Ford, R. J., et al. (2015). Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat. Med. 21, 166–172. doi: 10.1038/nm.3766
Hajduch, E., Rencurel, F., Balendran, A., Batty, I. J., Downes, C. P., and Hundal, H. S. (1999b). Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J. Biol. Chem. 274, 13563–13568. doi: 10.1074/jbc.274.19.13563

Hasegawa, Y., Suehiro, A., Higasa, S., Namba, M., and Kakishita, E. (2002). Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb. Res. 107, 319–323. doi: 10.1016/s0049-3848(02)00348-1

Hesler, L. K., Jobst, E. E., Sutton, G. M., Zhou, L., Borok, E., Thornton-Jones, Z., et al. (2006). Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Nature 51, 239–249. doi: 10.1038/nn.2006.6.004

Hesler, L. K., Ptechuk, N., Nonogaki, K., Zhou, L., Raber, J., Tung, L., et al. (2007). Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J. Neurosci. 27, 6956–6964. doi: 10.1523/JNEUROSCI.2584-06.2007

Henderson, D. C. (2002). Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drug Rev. 8, 17–89. doi: 10.1080/107039402906221602

Higgins, G. A., Fletcher, P. J., and Shanahan, W. R. (2020). Lorcarserin: a review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol. Ther. 205:101741. doi: 10.1016/j.pharmthera.2019.101747

Higgins, G. A., Silenksi, L. B., Lau, W., De Lannoy, I. A., Lee, D. K., Ishakova, J., et al. (2015). Evaluation of chemically diverse 5-HT2c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Psychopharmacology (Berl.) 226, 475–490. doi: 10.1007/s00213-012-2192-9

Ikeda, T., Ishida, Y., Nanno, R., Takeda, R., Abe, H., Nakamura, T., et al. (2009). Effects of intrabursal administration of newer antidepressants on mechanical allodynia in rats of neuropathic pain. Neurosci. Res. 63, 42–46. doi: 10.1016/j.neures.2008.10.002

Jean, A., Conductor, G., Manrique, C., Bouras, C., Berta, P., Hen, R., et al. (2007). Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CAMP in the nucleus accumbens. Proc. Natl. Acad. Sci. U S A. 104, 16335–16340. doi: 10.1073/pnas.0701741104

Jean, A., Laurent, L., Bockaert, J., Charnay, Y., Dusticier, N., Nioeullon, A., et al. (2012). The nucleus accumbens 5-HT(4)R-CART pathway ties anorexia to hyperactivity. Trans. Psychiatry 103:1073. doi: 10.1016/j.psc.2012.131

Janowicz-Unyil, M., Moorjani, R., and Kahn, A. H. (1994). Indications of pre- and post-synaptic 5-HT1A receptor interactions in feeding behavior and neuroendocrine regulation. Brain Res. 646, 247–257. doi: 10.1016/0006-8993(94)90086-5

Jones, L. A., Sun, E. W., Martin, A. M., and Keating, D. J. (2020). The ever-changing roles of serotonin. Int. J. Biochem. Cell Biol. 125:105776. doi: 10.1016/j.biocel.2020.105776

Khoshevisani, K., Baharifar, H., Torabi, F., Sadegh Afjejeh, M., Maleki, H., Honavarfard, E., et al. (2021). Serotonin level as a potent diabetes biomarker based on electrochemical sensing a new approach in a zebra fish model. Anal. Bioanal. Chem. 413, 1615–1627. doi: 10.1007/s00213-020-03122-5

Kim, H., Toyofuku, Y., Lynn, F. C., Chak, E., Uchida, T., Mizukami, H., et al. (2010). Serotonin regulates pancreatic beta cell mass during pregnancy. Nat. Med. 16, 804–808. doi: 10.1038/nm.2173

Kolodziejev, M., Bechade, C., Gervasi, N., Irinopoulou, T., Banas, S. M., Cordier, C., et al. (2015). Serotonin modulates developmental microglia via 5-HT2B receptors: potential implication during synaptic refinement of retinogeniculate projections. ACS Chem. Neurosci. 6, 1219–1229. doi: 10.1021/acschemneuro.5b00349

Korim, W. S., Bou Farah, L., McMullen, S., and Verbeiren, A. J. (2014). orexinergic activation of mediobasal prefrontal neurons modulates the dorsal sympathoexcitation to hypophyalseal glucocorticoid. Diab. Metab. Res. Rev. 30, 895–896. doi: 10.1002/dmrr.1373

Lalit, J., Karila, D., Dallempagne, P., and Rochais, C. (2017). Modulating 5-HT4 and 5-HT6 receptors in Alzheimer’s disease treatment. Future Med. Chem. 9, 781–795. doi: 10.4155/fmc-2017-0031

Leong, M. L., Gu, M., Speltz-Paiz, R., Stabura, E. I., Mottey, N., Steer, C. J., et al. (2011). Neural loss in the rostral ventromedial medulla in a rat model of neuropathic pain. J. Neurosci. 31, 17028–17039. doi: 10.1523/JNEUROSCI.1268-11.2011

Lewczuk, P., Prusik, M., Ziółkowska, N., Dabrowski, M., Martniuk, K., Hanuszewskas, M., et al. (2018). Effects of streptozotocin-induced diabetes on the pinnal gland in the domestic pig. Int. J. Mol. Sci. 19:3077. doi: 10.3390/ijms19103077

Li, S., Sun, C., Rong, P., Zhai, X., Zhang, J., Baker, M., et al. (2018). Auricular vagus nerve stimulation enhances central serotonergic function and

Frontiers in Cellular Neuroscience 14 frontiersin.org
inhibits diabetic neuropathy development in Zucker fatty rats. Mol. Pain 14:1744806818787368. doi: 10.1077/1744806818787368

Li, Y., Liu, J., Liu, X., Xu, C. J., Zhang, Q. L., Wang, Z. H., et al. (2019). Antidepressant-like action of single facial injection of botulinum neurotoxin a is associated with augmented 5-HT levels and BDNF/ERK/CREB pathways in mouse brain. Neurosci. Bull. 35, 661–672. doi: 10.1016/j.nebs.2019.03-06376

Li, Z., Chalanontit, A., Huang, Y. Y., Mann, J. T., Chen, H. Y., Ku, H. H., et al. (2007). Sperofoxae dismutate and catalase inhibit oxidized low-density lipoprotein-induced human aortic smooth muscle cell proliferation: role of cell-cycle regulation, mitogen-activated protein kinases, and transcription factors. Atherosclerosis 190, 124–134. doi: 10.1016/j.atherosclerosis.2006.02.044

Liu, Z., Dai, X., Zhang, H., Shi, R., Hui, Y., Jin, X., et al. (2020). Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat. Commun. 11:855. doi: 10.1038/s41467-020-14676-4

Lochhead, J. J., and Thorne, R. G. (2012). Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 64, 614–628. doi: 10.1016/j.addr.2011.11.002

Malek, Z. S., Dardente, H., Pevet, P., and Raison, S. (2005). Tissue-specific expression of tryptophan hydroxylase mRNAs in the rat midbrain: anatomical evidence and daily profiles. Eur. J. Neurosci. 22, 895–901. doi: 10.1111/j.1460-9568.2005.04264.x

Martin, A. M., Yabut, J. M., Choo, J. M., Page, A. J., Sun, E. W., Jessup, C. F., et al. (2007). Sperofoxae dismutate and catalase inhibit oxidized low-density lipoprotein-induced human aortic smooth muscle cell proliferation: role of cell-cycle regulation, mitogen-activated protein kinases, and transcription factors. Atherosclerosis 190, 124–134. doi: 10.1016/j.atherosclerosis.2006.02.044

Mathal, M. L. (2021). Has the bloom gone out for forskolin following the CAMELLIA-TIMI 50 trial? Expert Opin. Pharmacother. 22, 261–264. doi: 10.1080/14656640.2020.1858795

Oh, C. M., Namkung, J., Go, Y., Shong, K. E., Kim, K., Kim, H., et al. (2015). Regulation of systemic energy homeostasis by serotonin in adipose tissues. Nat. Commun. 6:6794. doi: 10.1038/ncomms7794

Oh, C. M., Park, S., and Kim, H. (2016). Serotonin as a new therapeutic target for diabetes mellitus and obesity. Diab. Metab. J. 40, 89–98. doi: 10.4093/dmj.2016.40.2.89

Oltvai, N. Z., and Lewis, B. P. (1996). G protein-coupled receptors: focus on 5-hydroxytryptamine receptors. Neuropharmacology 35, 319–324. doi: 10.1016/0028-3908(94)90060-4

Petricarz, M. H., Takada, Y., Takada, A., Fujita, M., Watanabe, I., Taminato, A., et al. (1992). Blood serotoninergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus. Thromb. Res. 66, 765–774. doi: 10.1016/0049-3898(92)90052-c

Politis, M., and Niccolini, F. (2015). Serotonin in Parkinson’s disease. Behav. Brain Res. 277, 136–145. doi: 10.1016/j.bbr.2014.07.037

Ponicke, K., Gergis, U., Buchwalow, I. B., Hauptmann, S., and Neumann, J. (2012). On the presence of serotonin in mammalian cardiomycocytes. Mol. Cell. Biochem. 365, 301–312. doi: 10.1007/s11010-012-1270-6

Prabahkar, A., Gupta, D., Kanade, P., and Radhakrishnan, M. (2015). Diabetes-associated depression: the serotonergic system as a novel multifunctional target. Indian J. Pharmacol. 47, 4–10. doi: 10.4103/0019-5479.153005

Reeves, D. C., and Lumniss, S. C. (2002). The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review). Mol. Membr. Biol. 19, 11–26. doi: 10.1108/09687680110110048

Ruat, M., Traifort, E., Arrang, J. M., Tardivel-Lacombe, J., Diaz, J., Leurs, R., et al. (1993). A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 193, 268–276. doi: 10.1016/0006-291X(93)91893-5

Sah, S. A., Feng, J., Liu, Y., Scrimgeour, L. A., El-Ahass, A., and Selke, F. W. (2018). Decreased contractile response of peripheral arterial to serotonin after CPB in patients with diabetes. Surgery 164, 288–293. doi: 10.1016/j.surg.2018.03.007

Sakimura, K., Maekawa, T., Sasagawa, K., Ishii, Y., Kume, S., and Ohtba, T. (2018). Depression-related behavioura and neuroendocrine changes in the Spontaneously Diabetic Torii (SDT) fatty rat, an animal model of type 2 diabetes mellitus. Clin. Exp. Pharmacol. Physiol. Online ahead of print. doi: 10.1111/1440-1681.12965

Sande, N. M., Wilkinson, C. W., Taborsky, G. J., Jr., Al-Noori, S., Daumen, W., et al. (2008). The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia. Am. J. Physiol. Endocrinol. Metab. 294, E383–E386. doi: 10.1152/ajpendo.00772.2007

Sano, H., and Yokoi, M. (2007). Striatal medium spiny neurons terminate in a distinct region in the lateral hypothalamic area and do not directly innervate orexin/hypocretin- or melanin-concentrating hormone-containing neurons. J. Neurosci. 27, 6948–6955. doi: 10.1523/NEURO.051311-111.2007

Sar, C. D., Gunduz, O., and Ulugol, A. (2019). Spinal serotonin and 5HT6 receptor levels during development of neuropathy and influence of blockade of these receptors on thermal hyperalgesia in diabetic mice. Drug Res (Stuttg) 69, 428–433. doi: 10.1055/a-0817-5464

Scirica, B. M., Bohula, E. A., Dwyer, J. P., Qamar, A., Inzucchi, S. E., Meguire, D. K., et al. (2019). Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial. Circulation 139, 366–375. doi: 10.1161/CIRCULATIONAHA.118.038341

Sohn, J. W., Xu, Y., Jones, J. E., Wickman, K., Williams, K. W., and Elmquist, J. K. (2011). Serotonin 2C receptor activates a distinct population of accreto pro-opiomelanocortin neurons via TRPC channels. Neuron 71, 488–497. doi: 10.1016/j.neuron.2011.06.012

Su, Y., Mao, N., Li, M., Dong, X., Lin, F. Z., Xu, Y., et al. (2013). Sarpogrelate inhibits the expression of ICAM-1 and monocyte-endothelial adhesion induced by high glucose in human endothelial cells. Mol. Cell. Biochem. 373, 195–199. doi: 10.1007/s11010-012-1490-9

Sudo, M., Minokoshi, Y., and Shimazu, T. (1991). Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am. J. Physiol. 261, E298–E303. doi: 10.1152/ajpendo.1991.261.3.E298
Sumara, G., Sumara, O., Kim, J. K., and Karsenty, G. (2012). Gut-derived serotonin is a multifunctional determinant to fasting adaptation. *Cell Metab.* 16, 588–600. doi: 10.1016/j.cmet.2012.09.014

Trento, M., Kucich, C., Tibaldi, P., Gennari, S., Tedesco, S., Balbo, M., et al. (2010). A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care. *J. Endocrinol. Invest.* 33, 624–628. doi: 10.1007/BF03346660

Tu, H., Cao, N., Gu, B., St, J., Chen, Z., and Andersson, K. E. (2015). Serotonin (5-HT)2A/2C receptor agonist (2,5-dimethoxy-4-idophenyl)-2-aminopropane hydrochloride (DOI) improves voiding efficiency in the diabetic rat. *BJU Int.* 116, 147–155. doi: 10.1111/bju.12684

Tuomainen, M., Lindstrom, J., Lehtonen, M., Auriola, S., Pihlajamaki, J., Peltonen, M., et al. (2018). Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals. *Nutrition Diab.* 8:35. doi: 10.1038/s41387-018-0046-9

Ueno, N., Inui, A., and Satoh, Y. (2010). The effect of mosapride citrate on constipation in patients with diabetes. *Diab. Res. Clin. Pract.* 87, 27–32. doi: 10.1016/j.diabres.2009.09.024

U.S. Food and Drug Administration (2012). FDA approves Belviq to treat some overweight or obese adults. *Home Healthc. Nurse* 30, 443–444.

Wade, P. R., Chen, J., Jaffe, B., Kassem, J. S., Blakey, R. D., and Gershon, M. D. (1996). Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. *J. Neurosci.* 16, 2352–2364. doi: 10.1523/JNEUROSCI.16-07-02352.1996

Yabut, J. M., Crane, J. D., Green, A. E., Keating, D. J., Khan, W. I., and Steinberg, G. R. (2019). Emerging roles for serotonin in regulating metabolism: new implications for an ancient molecule. *Endocr. Rev.* 40, 1092–1107. doi: 10.1210/er.2018-00283

Yamada, J., Sugimoto, Y., Noma, T., and Yoshikawa, T. (1998). Effects of the non-selective 5-HT receptor agonist, 5-carboxamidotryptamine, on plasma glucose levels in rats. *Eur. J. Pharmacol.* 359, 81–86. doi: 10.1016/S0014-2999(98)00617-7

Yamada, K., Niki, H., Nagai, H., Nishikawa, M., and Nakagawa, H. (2012). Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes. *J. Pharmacol. Sci.* 119, 243–250. doi: 10.1254/jphs.12009fp

Yi, C. X., Serlie, M. J., Ackermans, M. T., Foppen, E., Buijs, R. M., Sauerwein, H. P., et al. (2009). A major role for perifornical orexin neurons in the control of glucose metabolism in rats. *Diab. Metab. Rev. Rev.* 58, 1998–2005. doi: 10.2337/db09-0385

Yohn, C. N., Gergues, M. M., and Samuels, B. A. (2017). The role of 5-HT receptors in depression. *Mol. Brain* 10:28. doi: 10.1186/s13041-017-0306-y

Young, R. L., Lumsden, A. L., Martin, A. M., Schober, G., Pezos, N., Thazhath, S. S., et al. (2018). Augmented capacity for peripheral serotonin release in human obesity. *Int. J. Obesity* 42, 1880–1889. doi: 10.1038/s41366-018-0047-8

Zhang, G., and Stackman, R. W. Jr. (2015). The role of serotonin 5-HT2A receptors in memory and cognition. *Front. Pharmacol.* 6:225. doi: 10.3389/fphar.2015.00225

Zucker, M. B. (1944). A study of the substances in blood serum and platelets which stimulate smooth muscle. *Am. J. Physiology-Legacy Content* 142, 12–26. doi: 10.1152/ajpregu.1944.142.1.12